Overview

Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer

Status:
Withdrawn
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies how well arsenic trioxide and itraconazole work in treating patients with basal cell cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Itraconazole may help treat fungal infections in patients with basal cell cancer. Giving arsenic trioxide with itraconazole may work better in treating basal cell cancer.
Phase:
Early Phase 1
Details
Lead Sponsor:
Jean Yuh Tang
Collaborator:
National Cancer Institute (NCI)
Treatments:
Arsenic Trioxide
Hydroxyitraconazole
Itraconazole